FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Patients should be instructed to avoid spicy foods, ther...
A thin layer of FINACEA Gel, 15%, should be gently massaged into the affected areas on the face twice daily, in the morning and evening. Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
www.myfinacea.comFor Dermatologic Use Only-Not for Ophthalmic, Oral, or Intravaginal Use
Rx only
FINACEA® (azelaic acid) Gel, 15%, contains azelaic acid, a naturally occurring saturated dicarboxylic acid. Chemically, azelaic acid is 1,7-heptanedicarboxylic acid, with the molecular formula C9 H16 O4, a molecular weight of 188.22, and the structural formula:
Azelaic acid is a white, odorless crystalline solid that is poorly soluble in water at 20°C (0.24%), but freely soluble in boiling water and in ethanol.
Each gram of FINACEA Gel, 15%, contains 0.15 gm azelaic acid (15% w/w) as the active ingredient in an aqueous gel base containing benzoic acid (as a preservative), disodium EDTA, lecithin, medium-chain triglycerides, polyacrylic acid, polysorbate 80, propylene glycol, purified water, and sodium hydroxide to adjust pH.
The mechanism(s) by which azelaic acid interferes with the pathogenic events in rosacea are unknown.
The percutaneous absorption of azelaic acid after topical application of FINACEA Gel, 15%, could not be reliably determined. Mean plasma azelaic acid concentrations in rosacea patients treated with FINACEA Gel, 15%, twice daily for at least 8 weeks are in the range of 42 to 63.1 ng/mL. These values are within the maximum concentration range of 24.0 to 90.5 ng/mL observed in rosacea patients treated with vehicle only. This indicates that FINACEA Gel, 15%, does not increase plasma azelaic acid concentration beyond the range derived from nutrition and endogenous metabolism.
In vitro and human data suggest negligible cutaneous metabolism of 3H-azelaic acid 20% cream after topical application. Azelaic acid is mainly excreted unchanged in the urine, but undergoes some ß-oxidation to shorter chain dicarboxylic acids.
FINACEA Gel, 15%, was evaluated for the treatment of mild to moderate papulopustular rosacea in 2 clinical trials comprising a total of 664 (333 active to 331 vehicle) patients. Both trials were multicenter, randomized, double-blind, vehicle-controlled 12-week studies with identical protocols. Overall, 92.5% of patients were Caucasian and 73% of patients were women, and the mean age was 49 (range 21 to 86) years. Enrolled patients had mild to moderate rosacea with a mean lesion count of 18 (range 8 to 60) inflammatory papules and pustules. Subjects without papules and pustules, with nodules, rhinophyma, or ocular involvement, and a history of hypersensitivity to propylene glycol or to any other ingredients of the study drug were excluded. FINACEA Gel, 15%, or its vehicle were to be applied twice daily for 12 weeks; no other topical or systemic medication affecting the course of rosacea and/or evaluability was to be used during the studies. Patients were instructed to avoid spicy foods, thermally hot foods and drinks, and alcoholic beverages during the study, and to use only very mild soaps or soapless cleansing lotion for facial cleansing.
The primary efficacy endpoints were both
CLEAR: | No papules and/or pustules; no or residual erythema; no or mild to moderate telangiectasia |
MINIMAL: | Rare papules and/or pustules; residual to mild erythema; mild to moderate telangiectasia |
MILD: | Few papules and/or pustules; mild erythema; mild to moderate telangiectasia |
MILD TO MODERATE: | Distinct number of papules and/or pustules; mild to moderate erythema; mild to moderate telangiectasia |
MODERATE: | Pronounced number of papules and/or pustules; moderate erythema; mild to moderate telangiectasia |
MODERATE TO SEVERE: | Many papules and/or pustules, occasionally with large inflamed lesions; moderate erythema; moderate degree of telangiectasia |
SEVERE: | Numerous papules and/or pustules, occasionally with confluent areas of inflamed lesions; moderate or severe erythema; moderate or severe telangiectasia |
Primary efficacy assessment was based on the intent-to-treat (ITT) population with last observation carried forward (LOCF).
Both studies demonstrated a statistically significant difference in favor of FINACEA Gel, 15%, over its vehicle in reducing the number of inflammatory papules and pustules associated with rosacea (Table 1) and with success on the IGA in the ITT-LOCF population at the end of treatment.
Study One FINACEA Gel,15% N = 164 | Study One VEHICLE N = 165 | Study Two FINACEA Gel,15% N = 167 | Study Two VEHICLE N = 166 | |
Mean Lesion Count Baseline | 17.5 | 17.6 | 17.9 | 18.5 |
End of Treatment | 6.8 | 10.5 | 9.0 | 12.1 |
Mean Percent Reduction End of Treatment | 57.9% | 39.9% | 50.0% | 38.2% |
* ITT population with last observation carried forward (LOCF);
Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.
FINACEA Gel, 15%, was superior to the vehicle with regard to success based on the investigator's global assessment of rosacea on a 7-point static score at the end of treatment, (ITT population; Table 2).
Study One FINACEA Gel, 15% N = 164 | Study One VEHICLE N = 165 | Study Two FINACEA Gel, 15% N = 167 | Study Two VEHICLE N = 166 | |
CLEAR, MINIMAL or MILD at End of Treatment (%of Patients) | 61% | 40% | 61% | 48% |
* ITT population with last observation carried forward (LOCF);
FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Patients should be instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to use only very mild soaps or soapless cleansing lotion for facial cleansing.
FINACEA Gel, 15%, is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation.
FINACEA Gel, 15%, is for dermatologic use only, and not for ophthalmic, oral or intravaginal use.
There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.
Contact with the eyes should be avoided. If sensitivity or severe irritation develops with the use of FINACEA Gel, 15%, treatment should be discontinued and appropriate therapy instituted.
In a transgenic mouse study, chronic use of FINACEA Gel led to an increased number of animals with papillomas at the treatment site (see PRECAUTIONS: Carcinogenesis, Mutagenesis, and Impairment of Fertility). The clinical relevance of the findings in animal studies to humans is not clear.
Patients using FINACEA Gel, 15%, should receive the following information and instructions:
There have been no formal studies of the interaction of FINACEA Gel, 15%, with other drugs.
Systemic long-term animal studies have not been performed to evaluate the carcinogenic potential of azelaic acid. In a 26-week dermal carcinogenicity study using transgenic (Tg.AC) mice, FINACEA Gel, 15%, and the gel vehicle, when applied once or twice daily, did not increase the number of female Tg.AC animals with papillomas at the treatment site. No statistically significant increase in the number of animals with papillomas at the treatment site was observed in male Tg.AC animals after once daily application. After twice daily application, FINACEA Gel, 15%, and the gel vehicle induced a statistically significant increase in the number of male animals with papillomas at the treatment site when compared to untreated males. This suggests that the positive effect may be associated with the vehicle application. The clinical relevance of the findings in animals to humans is not clear.
Azelaic acid was not mutagenic or clastogenic in a battery of in vitro (Ames assay, HGPRT in V79 cells {Chinese hamster lung cells}, and chromosomal aberration assay in human lymphocytes) and in vivo (dominant lethal assay in mice and mouse micronucleus assay) genotoxicity tests.
Oral administration of azelaic acid at dose levels up to 2500 mg/kg/day (162 times the maximum recommended human dose based on body surface area) did not affect fertility or reproductive performance in male or female rats.
There are no adequate and well-controlled studies of topically administered azelaic acid in pregnant women. The experience with FINACEA Gel, 15%, when used by pregnant women is too limited to permit assessment of the safety of its use during pregnancy.
Dermal embryofetal developmental toxicology studies have not been performed with azelaic acid, 15%, gel. Oral embryofetal developmental studies were conducted with azelaic acid in rats, rabbits, and cynomolgus monkeys. Azelaic acid was administered during the period of organogenesis in all three animal species. Embryotoxicity was observed in rats, rabbits, and monkeys at oral doses of azelaic acid that generated some maternal toxicity. Embryotoxicity was observed in rats given 2500 mg/kg/day (162 times the maximum recommended human dose based on body surface area), rabbits given 150 or 500 mg/kg/day (19 or 65 times the maximum recommended human dose based on body surface area) and cynomolgus monkeys given 500 mg/kg/day (65 times the maximum recommended human dose based on body surface area) azelaic acid. No teratogenic effects were observed in the oral embryofetal developmental studies conducted in rats, rabbits and cynomolgus monkeys.
An oral peri- and post-natal developmental study was conducted in rats. Azelaic acid was administered from gestational day 15 through day 21 postpartum up to a dose level of 2500 mg/kg/day. Embryotoxicity was observed in rats at an oral dose that generated some maternal toxicity (2500 mg/kg/day; 162 times the maximum recommended human dose based on body surface area). In addition, slight disturbances in the postnatal development of fetuses was noted in rats at oral doses that generated some maternal toxicity (500 and 2500 mg/kg/day; 32 and 162 times the maximum recommended human dose based on body surface area). No effects on sexual maturation of the fetuses were noted in this study.
Because animal reproduction studies are not always predictive of human response, this drug should be used only if clearly needed during pregnancy.
Equilibrium dialysis was used to assess human milk partitioning in vitro. At an azelaic acid concentration of 25 μg/mL, the milk/ plasma distribution coefficient was 0.7 and the milk/buffer distribution was 1.0, indicating that passage of drug into maternal milk may occur. Since less than 4% of a topically applied dose of azelaic acid cream, 20%, is systemically absorbed, the uptake of azelaic acid into maternal milk is not expected to cause a significant change from baseline azelaic acid levels in the milk. However, caution should be exercised when FINACEA Gel, 15%, is administered to a nursing mother.
Safety and effectiveness of FINACEA Gel, 15%, in pediatric patients have not been established.
Clinical studies of FINACEA Gel, 15%, did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
Overall, treatment related adverse events, including burning, stinging/tingling, dryness/tightness/scaling, itching, and erythema/irritation/redness, were 19.4% (24/124) for FINACEA Gel, 15%, and 7.1% (9/127) for the active comparator gel at 15 weeks.
In two vehicle controlled, and one active controlled U.S. clinical studies, treatment safety was monitored in 788 patients who used twice daily FINACEA Gel, 15%, for 12 weeks (N=333) or for 15 weeks (N=124), or the gel vehicle (N=331) for 12 weeks.
FINACEA Gel, 15% N=457 (100%) | Vehicle N=331 (100%) | |||||
Mild n=99 (22%) | Moderate n=61 (13%) | Severe n=27 (6%) | Mild n=46 (14%) | Moderate n=30 (9%) | Severe n=5 (2%) | |
Burning/ stinging/ tingling | 71 (16%) | 42 (9%) | 17 (4%) | 8 (2%) | 6 (2%) | 2 (1%) |
Pruritus | 29 (6%) | 18 (4%) | 5 (1%) | 9 (3%) | 6 (2%) | 0 (0%) |
Scaling/dry skin/xerosis | 21 (5%) | 10 (2%) | 5 (1%) | 31 (9%) | 14 (4%) | 1 (<1%) |
Erythema/ irritation | 6 (1%) | 7 (2%) | 2 (<1%) | 8 (2%) | 4 (1%) | 2 (1%) |
Contact dermatitis | 2 (<1%) | 3 (1%) | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) |
Edema | 3 (1%) | 2 (<1%) | 0 (0%) | 3 (1%) | 0 (0%) | 0 (0%) |
Acne | 3 (1%) | 1 (<1%) | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) |
* Subjects may have >1 cutaneous adverse event; thus, the sum of the frequencies of preferred terms may exceed the number of subjects with at least 1 cutaneous adverse event.
FINACEA Gel, 15%, and its vehicle caused irritant reactions at the application site in human dermal safety studies. FINACEA Gel, 15%, caused significantly more irritation than its vehicle in a cumulative irritation study. Some improvement in irritation was demonstrated over the course of the clinical studies, but this improvement might be attributed to subject dropouts. No phototoxicity or photoallergenicity were reported in human dermal safety studies.
In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.
Post-marketing safety-Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure with FINACEA Gel, 15%, to the eye (see PRECAUTIONS).
FINACEA Gel, 15%, is intended for cutaneous use only. If pronounced local irritation occurs, patients should be directed to discontinue use and appropriate therapy should be instituted (See PRECAUTIONS).
A thin layer of FINACEA Gel, 15%, should be gently massaged into the affected areas on the face twice daily, in the morning and evening. Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.
FINACEA Gel, 15%, is supplied in tubes in the following size:
FINACEA Gel, 15% – 50 g tube – NDC 10922-825-02
Storage
Store at 25°C (77°F); excursions permitted between 15–30°C (59–86°F) [see USP Controlled Room Temperature].
Distributed under license; U.S. Patent No 6,534,070
© 2010, Intendis, Inc. All rights reserved. July 2010
Manufactured by Intendis Manufacturing S.p.A., Segrate, Milan, Italy
Distributed by:
Intendis
Morristown, NJ 07962
Intendis is part of the Bayer Group
6706803
Finacea plus
NDC 10922-826-10
Rx only
Finacea (azelaic acid) Gel, 15%–Plus
Dispense as a Complete Package
Package contains: Finacea® (azelaic acid) Gel, 15%, 50 g
For Dermatologic Use Only - Not For Ophthalmic Use
Complimentary CeraVe® Hydrating Cleanser 3 fl oz (87 mL)
CeraVe® Moisturizing Lotion 3 fl oz (87 mL)
Patient Information Brochure
Finacea Gel, 15%–50 g Tube
NDC 10922-825-02
For Dermatologic Use Only
Not For Ophthalmic Use
Finacea®
(azelaic acid) Gel 15%
50 grams
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1041518 | azelaic acid 15 % Topical Gel | PSN | 5 |
| 1043748 | Finacea 15 % Topical Gel | PSN | 5 |
| 1043748 | azelaic acid 0.15 MG/MG Topical Gel [Finacea] | SBD | 5 |
| 1041518 | azelaic acid 0.15 MG/MG Topical Gel | SCD | 5 |
| 1041518 | azelaic acid 15 % Topical Gel | SY | 5 |
| 1043748 | Finacea 0.15 MG/MG Topical Gel | SY | 5 |
| 1043748 | Finacea 15 % Topical Gel | SY | 5 |
| 1043748 | Finacea Plus (azelaic acid 0.15 MG/MG) Topical Gel | SY | 5 |
| Class | Version | Type | Effective |
|---|---|---|---|
| AZELAIC ACID Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 4b7700e3-6e0e-45e5-9d22-6f754d61386e | Product name | 2 | 20250304 |
| c6f86816-7da6-43ea-8c25-ac9758311cc5 | Product name | 1 | 20220118 |
| 6c6fc281-9445-2e9e-1c29-a09ddbc4299c | Product name | 2 | 20200213 |
| 252e11b6-1a9a-4283-a242-df2c129c496d | Product name | 3 | 20170717 |
| 2a856070-cbe7-4f85-be0f-09885ff91196 | Product name | 1 | 20150806 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 10922-825-02 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d63a-cd31-e053-dbdaa90ab51a | Finacea ® (azelaic acid) Gel, 15% |
| 10922-826-10 | 2019-11-27 | C162847 | 48780-1 | 9855d018-d63a-cd31-e053-dbdaa90ab51a | Finacea ® (azelaic acid) Gel, 15% |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 10922-825-02 | Finacea | 50 g in 1 TUBE | GEL | 50 | 5 | |
| 10922-825-02 | Finacea | 1 in 1 CARTON | GEL | 1 | 5 | |
| 10922-826-10 | Finacea | 1 in 1 CARTON | KIT | 1 | 5 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 10922-825 | FINACEA (AZELAIC ACID) GEL FINACEA (AZELAIC ACID) KIT [INTENDIS INC.] | 5 | Legacy NDC, 2 package rows | 20130507_63773349-0295-4d56-a72e-0d7cade88ddb.zip |
| 10922-826 | FINACEA (AZELAIC ACID) GEL FINACEA (AZELAIC ACID) KIT [INTENDIS INC.] | 5 | Legacy NDC, 1 package rows | 20130507_63773349-0295-4d56-a72e-0d7cade88ddb.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 10922-825-02 | GM - Gram | 10922-825 | 86050828-5e8f-4bf5-ac59-897918611e0f | 1 | 2012-07-24 |
| 10922-826-10 | EA - Each | 10922-826 | 5fc1cab0-2057-4585-a181-55457be4c4d2 | 1 | 2013-06-04 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| AZELAIC ACID | ACTIVE INGREDIENT | F2VW3D43YT | 5 | |
| AZELAIC ACID | ACTIVE MOIETY | F2VW3D43YT | 5 | |
| 1,2-DIARACHIDOYL-SN-GLYCERO-3-PHOSPHOCHOLINE | INACTIVE INGREDIENT | HE0P2D9ZLS | 5 | |
| BEHENTRIMONIUM METHOSULFATE | INACTIVE INGREDIENT | 5SHP745C61 | 5 | |
| BENZOIC ACID | INACTIVE INGREDIENT | 8SKN0B0MIM | 5 | |
| CERAMIDE 1 | INACTIVE INGREDIENT | 5THT33P7X7 | 5 | |
| CERAMIDE 3 | INACTIVE INGREDIENT | 4370DF050B | 5 | |
| CERAMIDE 6 II | INACTIVE INGREDIENT | F1X8L2B00J | 5 | |
| CETOSTEARYL ALCOHOL | INACTIVE INGREDIENT | 2DMT128M1S | 5 | |
| CETYL ALCOHOL | INACTIVE INGREDIENT | 936JST6JCN | 5 | |
| CHOLESTEROL | INACTIVE INGREDIENT | 97C5T2UQ7J | 5 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 5 | |
| EDETATE DISODIUM | INACTIVE INGREDIENT | 7FLD91C86K | 5 | |
| GLYCERIN | INACTIVE INGREDIENT | PDC6A3C0OX | 5 | |
| GLYCERYL MONOSTEARATE | INACTIVE INGREDIENT | 230OU9XXE4 | 5 | |
| HYALURONIC ACID | INACTIVE INGREDIENT | S270N0TRQY | 5 | |
| MEDIUM-CHAIN TRIGLYCERIDES | INACTIVE INGREDIENT | C9H2L21V7U | 5 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 5 | |
| PHYTOSPHINGOSINE | INACTIVE INGREDIENT | GIN46U9Q2Q | 5 | |
| POLYACRYLIC ACID (250000 MW) | INACTIVE INGREDIENT | 9G2MAD7J6W | 5 | |
| POLYGLYCERYL-3 DIISOSTEARATE | INACTIVE INGREDIENT | 46P231IQV8 | 5 | |
| POLYOXYL 20 CETOSTEARYL ETHER | INACTIVE INGREDIENT | YRC528SWUY | 5 | |
| POLYOXYL 40 STEARATE | INACTIVE INGREDIENT | 13A4J4NH9I | 5 | |
| POLYSORBATE 20 | INACTIVE INGREDIENT | 7T1F30V5YH | 5 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 5 | |
| POTASSIUM PHOSPHATE, DIBASIC | INACTIVE INGREDIENT | CI71S98N1Z | 5 | |
| POTASSIUM PHOSPHATE, UNSPECIFIED FORM | INACTIVE INGREDIENT | B7862WZ632 | 5 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 5 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 5 | |
| SODIUM HYDROXIDE | INACTIVE INGREDIENT | 55X04QC32I | 5 | |
| SODIUM LAUROYL LACTYLATE | INACTIVE INGREDIENT | 7243K85WFO | 5 | |
| STEARYL ALCOHOL | INACTIVE INGREDIENT | 2KR89I4H1Y | 5 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 5 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 10922-825 | 10922-825-02 |
| 10922-826 | 10922-826-10 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | POWDER, FOR SOLUTION / ORAL | 13 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / TOPICAL | 39 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 0.4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | PASTE, DENTIFRICE / DENTAL | 0.05 %w/w | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | DROPS / OPHTHALMIC | 0.05 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION, CONCENTRATE / ORAL | 0.2 mg/1ml | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | TABLET, CHEWABLE / ORAL | 1 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | AEROSOL, METERED / RESPIRATORY (INHALATION) | ADJ PH | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ELIXIR / ORAL | 200 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET / SUBLINGUAL | 1.23 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | CREAM / TOPICAL | 14 mg | ||
| MEDIUM-CHAIN TRIGLYCERIDES | MEDIUM-CHAIN TRIGLYCERIDES | C9H2L21V7U | GEL / TOPICAL | 12 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | OINTMENT / TOPICAL | 1 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / OPHTHALMIC | 1.5 %w/v | ||
| CETYL ALCOHOL | CETYL ALCOHOL | 936JST6JCN | TABLET, COATED / ORAL | 0.25 mg | ||
| POTASSIUM PHOSPHATE, DIBASIC | DIBASIC POTASSIUM PHOSPHATE | CI71S98N1Z | SOLUTION / ORAL | 890 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVITREAL | 0.02 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SPRAY, METERED / NASAL | ADJ PH | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | CAPSULE / ORAL | 14 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SWAB / TOPICAL | 34.6 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / NASAL | 0.2 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SOLUTION / AURICULAR (OTIC) | 0.2 %w/w | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS | ADJ PH | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION / INTRAVENOUS | 4680 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRA-AMNIOTIC | ADJ PH | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | CAPSULE, EXTENDED RELEASE / ORAL | 9.43 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / TOPICAL | 24 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRATUMOR | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / ENDOTRACHEAL | ADJ PH | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | GEL / OPHTHALMIC | 396 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | LOTION / TOPICAL | 15 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | INJECTION / SUBCUTANEOUS | 1.4 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | 0.35 %w/v | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SUSPENSION / OPHTHALMIC | 58 mg | ||
| POLYOXYL 20 CETOSTEARYL ETHER | POLYOXYL 20 CETOSTEARYL ETHER | YRC528SWUY | AEROSOL, FOAM / TOPICAL | 374 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| BENZOIC ACID | BENZOIC ACID | 8SKN0B0MIM | SUSPENSION / ORAL | 15 mg | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | LOTION / TOPICAL | 177 mg | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION, EXTENDED RELEASE / INTRA-ARTICULAR | ADJ PH | ||
| GLYCERYL MONOSTEARATE | GLYCERYL MONOSTEARATE | 230OU9XXE4 | TABLET, CHEWABLE / ORAL | 1 mg | ||
| POLYSORBATE 20 | POLYSORBATE 20 | 7T1F30V5YH | SOAP / TOPICAL | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| POLYOXYL 20 CETOSTEARYL ETHER | POLYOXYL 20 CETOSTEARYL ETHER | YRC528SWUY | GEL / TOPICAL | 2 %w/w | ||
| GLYCERIN | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAVENOUS | 33750 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INTRAMUSCULAR | 78 mg | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| POLYACRYLIC ACID (250000 MW) | POLYACRYLIC ACID (250000 MW) | 9G2MAD7J6W | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RESPIRATORY (INHALATION) | 0.03 %w/w | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | CONCENTRATE / ORAL | 1 mg/1ml | ||
| CETOSTEARYL ALCOHOL | CETOSTEARYL ALCOHOL | 2DMT128M1S | TABLET, EXTENDED RELEASE / ORAL | 800 mg | ||
| POLYOXYL 40 STEARATE | POLYOXYL 40 STEARATE TYPE I | 13A4J4NH9I | OINTMENT / TOPICAL | NA | ||
| POLYACRYLIC ACID (250000 MW) | POLYACRYLIC ACID (250000 MW) | 9G2MAD7J6W | SYSTEM / TOPICAL | 196 mg | ||
| EDETATE DISODIUM | EDETATE DISODIUM | 7FLD91C86K | SUSPENSION / OPHTHALMIC | 0.06 %w/v | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRA-ARTERIAL | ADJ PH | ||
| SODIUM HYDROXIDE | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / IRRIGATION | ADJ PH | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / TOPICAL | 0.24 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021470-001 | FINACEA | AZELAIC ACID | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 |
| Application-product | TE code |
|---|---|
| N021470-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N021470-001 | FINACEA | 15% | GEL / TOPICAL | AB | RLD, RS | 2002-12-24 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021470-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N021470-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N021470-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021470-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N021470-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021470-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021470-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021470-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021470-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021470-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021470-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N021470-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021470-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021470-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021470-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N021470-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021470-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N021470-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N021470-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N021470-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N021470-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N021470-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021470-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N021470-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N021470-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N021470-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N021470-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N021470-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N021470-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021470-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N021470-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N021470-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021470-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021470-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021470-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021470-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N021470-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N021470-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021470-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N021470-001 | AB | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| a7594a20-f46e-4b33-91d5-410cc5e97b8d | 63773349-0295-4d56-a72e-0d7cade88ddb | 2011-04-12 | Warnings, Adverse reactions | a7594a20-f46e-4b33-91d5-410cc5e97b8d 63773349-0295-4d56-a72e-0d7cade88ddb |
Adverse event summaries are temporarily unavailable. Other product information remains available.